CD20 Cytoplasmic Antibody, anti-human, REAfinity™

Name: CD20 Cytoplasmic Antibody, anti-human, REAfinity™
Availability: InStock

CD20 Cytoplasmic Antibody, anti-human, REAfinity™

Clone:

REA543

Type of antibody:

Primary antibodies, Recombinant antibodies

Isotype:

recombinant human IgG1

Applications:

ICFC, MICS, IF, IHC

Product data and images for CD20 Cytoplasmic Antibody, anti-human, REAfinity™

Figures

Figure 1

Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A . Cells were then stained with CD20 Cytoplasmic antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant

^®

Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals.

View details Figure 1 Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A . Cells were then stained with CD20 Cytoplasmic antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant ^® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals.	View details Figure 1 Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A . Cells were then stained with CD20 Cytoplasmic antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant ^® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals.
View details Figure 1 Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A . Cells were then stained with CD20 Cytoplasmic antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant ^® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals.	View details Figure 1 Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A . Cells were then stained with CD20 Cytoplasmic antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant ^® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals.
View details Figure 1 Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A . Cells were then stained with CD20 Cytoplasmic antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant ^® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals.	View details Figure 1 Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A . Cells were then stained with CD20 Cytoplasmic antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant ^® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals.
View details Figure 1 Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A . Cells were then stained with CD20 Cytoplasmic antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant ^® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals.	View details Figure 1 Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A . Cells were then stained with CD20 Cytoplasmic antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant ^® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals.
View details Figure 1 Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A . Cells were then stained with CD20 Cytoplasmic antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant ^® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals.	View details Figure 1 Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A . Cells were then stained with CD20 Cytoplasmic antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant ^® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals.

Specifications for CD20 Cytoplasmic Antibody, anti-human, REAfinity™

Overview

Clone REA543 recognizes the cytoplasmic domain of the human CD20 antigen, a non-glycosylated transmembrane protein of 33–37 kDa that is expressed on B lineage cells from the pre–B cell stage to the B cell lymphoblast stage. The antigen is further expressed on most malignant B cells. CD20 is not found on early B cell progenitors or plasma cells. Oligomers of CD20 form a Ca

²⁺

channel and might function in the regulation of local responses during B cell activation.

In vitro

effects of CD20-specific antibodies on resting B cells indicate that CD20 is able to transduce an extracellular signal affecting the G0/G1 cell cycle transition. Studies have demonstrated that CD20-initiated intracellular signals involve tyrosine kinase activation and that CD20 is tightly associated with both serine and tyrosine kinases.

Additional information: Clone REA543 displays negligible binding to Fc receptors.

Detailed product information

Technical specifications

Clone	REA543
Clonality	monoclonal
Isotype	recombinant human IgG1
Isotype control	REA Control Antibody (I), human IgG1
Host	cell line
Type of antibody	Primary antibodies, Recombinant antibodies
Species	human
Antigen	CD20 Cytoplasmic
Molecular mass of antigen [kDa]	33
Distribution of antigen	B cells
Entrez Gene ID	931
RRID	AB_2656085, AB_2656086, AB_2656087, AB_2656088, AB_2656089, AB_2656090, AB_2656091, AB_2656092

Reviews for CD20 Cytoplasmic Antibody, anti-human, REAfinity™

Human Anti-CD20-APC-Vio770 Antibody

CD20 Cytoplasmic-APC-Vio770, human (130-108-292)

This anti-CD20 antibody was tested in order to establish a panel to describe and distinguish peripheral blood lymphocytes (from human PBMCs). We are particularly interested in the innate compartment of lymphocytes, and use bright CD20 and CD19 recognizing antibodies to identify and exclude B lymphocytes. The Anti-CD20-APC-Vio770 human antibody from Miltenyi Biotec is a mouse monoclonal antibody to LT20 to CD20.

Write a review

References for CD20 Cytoplasmic Antibody, anti-human, REAfinity™

Publications

Einfeld, D. A. et al. (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 7(3): 711-717
Deans, J. P. et al. (1995) Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J. Biol. Chem. 270(38): 22632-22638
Vaughan, A. T. et al. (2015) Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain. J. Biol. Chem. 290(9): 5424-5437

Data and images